Accessibility Menu
Imugene logo

Imugene(ASX) IMU

Market CapA$40.16MMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.
Since IPO (2002)-98%
5 YearN/A
1 Year-71%
1 Month-14%
A$0.08
+0.00%
+0.00Today
Imugene last closing stock price
MetricPriceDate
Last closeAUD 0.082026-08-13
Imugene stock price return by period
PeriodPrice returnPrice at period startPeriod start date
1 week-1.19%AUD 0.082026-08-06
1 month-14.43%AUD 0.102026-07-14
3 month-12.63%AUD 0.102026-05-15
Year to date-77.26%AUD 0.372025-12-31
1 year-70.88%AUD 0.292025-08-13
Since inception-97.5%AUD 3.292002-09-02

Imugene Financials at a Glance

Market Cap

A$40.16MMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.

Revenue (TTM)

A$1.30M

Net Income (TTM)

-A$187.81M

EPS (TTM)

-A$0.22

P/E Ratio

-0.37

Dividend

A$0.00

Beta (Volatility)

0.15 (Low)

Price

A$0.08

Volume

93,680

Open

A$0.08

Previous Close

A$0.08

Daily Range

A$0.08 - A$0.08

52-Week Range

A$0.08 - A$0.46

Estimated Earnings Date

Sep 2, 2026

IMU News

No articles available.

Motley Fool Moneyball Superscore

Our CEO Is Handing Members His Secret Weapon

It's called Motley Fool Moneyball, our new proprietary AI tool

We spent over half a million dollars in R&D to build a tool that makes stock research faster, sharper, and smarter. Our analysts use it every day, and now, you can too.

Get Access Now

About Imugene

Imugene Limited is a clinical-stage immuno-oncology company focused on developing innovative immunotherapies to activate the immune system in cancer patients. The company is headquartered in Sydney, Australia, and is dedicated to eradicating tumors through a range of advanced therapies.

Products and Services
  • Azer-cel: Allogeneic CAR T cell therapy in phase 1 trial for non-Hodgkin lymphoma
  • CF33 VAXINIA: Oncolytic virus therapy in phase 1 trial for advanced solid tumors
  • HER-VAXX: B-cell immunotherapy vaccine targeting metastatic gastric cancer, completed phase 2 trial
Growth Outlook
  • Strong pipeline with multiple therapies in various clinical trial phases
  • Recent partnerships enhance research capabilities and market reach
  • Increasing global demand for innovative cancer treatments supports growth potential
Financial Highlights
  • Recent quarterly revenue of AUD 8.068 million, showing potential for growth
  • Cash and cash equivalents of AUD 14.136 million as of December 2025
  • Operating expenses of AUD 35.217 million indicate significant investment in R&D
Imugene Limited is positioned in the biotechnology sector, focusing on groundbreaking therapies that leverage the body's immune system to combat cancer. The company’s lead products are in various stages of clinical trials, showcasing a commitment to innovation in cancer treatment. The recent quarterly revenue indicates a positive trajectory, while the substantial investment in research and development reflects a strategic focus on advancing its product pipeline. With a strong cash position, Imugene is well-equipped to navigate the challenges of clinical development and capitalize on the growing demand for effective cancer therapies.
AI Generated • Jul 22, 2026

Industry

Biotechnology

Sector

Health Care

Employees

23

CEO

Leslie Chong

Website

imugene.com

Headquarters

Sydney, NSW 2000, AU

IMU Financials

Key Financial Metrics (TTM)

Gross Margin

-65.91%

Operating Margin

-1960.77%

Net Income Margin

-1864.12%

Return on Equity

-134.65%

Return on Capital

-127.40%

Return on Assets

-86.46%

Earnings Yield

-2.70%

Dividend Yield

0.00%

Payout Ratio

0.00%

Stock Overview

Market Cap

A$40.16MMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.

Shares Outstanding

489.72M

Volume

93.68K

Avg. Volume

3.48M

Financials (TTM)

Gross Profit

-A$3.91M

Operating Income

-A$178.92M

EBITDA

-A$178.96M

Operating Cash Flow

-A$150.44M

Capital Expenditure

-A$5.51M

Free Cash Flow

-A$155.95M

Cash & ST Invst.

A$14.14M

Total Debt

A$5.02M

Imugene Performance Analysis

Imugene annual revenue and year-over-year revenue growth by fiscal year
Fiscal yearPeriod endRevenueYoY growth
20222022-06-30AUD 0N/A
20232023-06-30AUD 0N/A
20242024-06-30AUD 0N/A
20252025-06-30AUD 0N/A
Imugene sequential (quarter-over-quarter) revenue growth by fiscal quarter
Fiscal quarterPeriod endQoQ growth
Q42024-06-30-138.4%
Q22024-12-31140.6%
Q42025-06-30149.5%
Q22025-12-31-100.0%
Imugene annual diluted earnings per share and year-over-year EPS growth by fiscal year
Fiscal yearPeriod endDiluted EPSYoY growth
20222022-06-30AUD -0.23N/A
20232023-06-30AUD -0.21-10.1%
20242024-06-30AUD -0.72249.6%
20252025-06-30AUD -0.32-56.1%
Imugene sequential (quarter-over-quarter) diluted earnings per share growth by fiscal quarter
Fiscal quarterPeriod endQoQ growth
Q42024-06-30-11.8%
Q22024-12-3142.1%
Q42025-06-3057.2%
Q22025-12-31-38.0%

Revenue Growth Rate

Annual and quarterly growth comparison

Currently no data to display.

Earnings Per Share Growth Rate

Annual and quarterly EPS growth comparison

Quarterly Performance

Name
Q2 2026YOY CHG

Revenue

A$0.00

-100.0%

Gross Profit

-A$5.21M

-164.5%

Gross Margin

0.00%

N/A

Market Cap

A$40.16MMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.

N/A

Market Cap/Employee

A$2.68M

N/A

Employees

15

N/A

Net Income

-A$37.82M

+45.0%

EBITDA

-A$40.07M

+46.3%

Quarterly Fundamentals

Name
Q2 2026YOY CHG

Total Cash

A$14.14M

-89.9%

Total Debt

A$5.02M

+20.2%

Accounts Receivable

A$4.41M

-78.4%

Inventory

A$1.67M

N/A

Long Term Debt

A$48.25K

-98.8%

Short Term Debt

A$4.98M

N/A

Return on Assets

-86.46%

N/A

Return on Invested Capital

-1.25%

N/A

Free Cash Flow

-A$25.97M

+56.7%

Operating Cash Flow

-A$25.97M

+46.4%

Other Investments to Explore

People Also Watch

Symbol / CompanyPricePrice Chg
RAD.AXRadiopharm Theranostics Limited
A$0.01+0.00%
EZZ.AXEZZ Life Science Holdings Limited
A$0.47-0.00%
PCK.AXPainChek Limited
A$0.10+0.00%
BIO.AXBiome Australia Limited
A$0.29-1.69%

Trending Stocks

Symbol / CompanyPricePrice Chg
ONDSOndas
$8.91-0.09%
SMCISuper Micro Computer
$39.16+0.04%
SPCXSpace Exploration Technologies
$141.29-0.03%
TSLLDirexion Shares ETF Trust - Direxion Daily Tsla Bull 2x ETF
$8.64+0.07%

Questions About IMU

What is the current price of Imugene?

Imugene is trading at A$0.08 per share.

What is the 52-week range for Imugene?

Over the past 52 weeks, Imugene has traded between A$0.08 and A$0.46.

How much debt does Imugene have?

As of the most recent reporting period, Imugene reported total debt of A$10.65M.

How much cash does Imugene have on hand?

Imugene reported A$21.94M in cash and cash equivalents in its most recent financial results.

What is Imugene’s dividend yield?

Imugene does not currently have a dividend yield.

Premium Investing Services

Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.

View Premium Services